Medication info

Bacirova Injection (Acyclovir)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Acyclovir›250mg / 1 vial
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
This medication is a white powder or granules contained in a colorless and transparent vial to be dissolved before use for injection.
Packaging
5 vials/box
Approval status
Active

MFDS item code 199802268 · Notified 1998.02.28 · Insurance code 657800841

Summary

Main use
Treatment and prevention of herpes simplex (encephalitis, genital herpes, etc.); treatment of chickenpox and shingles
Who receives it
Adults · Children
Adult administration
For injection, administer by slow intravenous drip infusion over at least 1 hour at each dose. A treatment period of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg every 8 hours. Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this drug 5 mg/kg every 8 hours. Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer this drug 10 mg/kg every 8 hours. Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this drug 10 mg/kg every 8 hours. Prevention of herpes simplex virus infections in immunocompromised patients: Consider this treatment when oral administration is not possible. Determine the treatment duration according to the period of risk of infection. When acyclovir is administered intravenously to obese patients based on actual body weight, plasma concentrations may increase. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or elderly patients. Creatinine clearance 25~50 mL/min: Administer the recommended dose for the above indication every 12 hours. Creatinine clearance 10~25 mL/min: Administer the recommended dose for the above indication every 24 hours. Creatinine clearance 0 (anuria)~10 mL/min: In patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg) every 24 hours. In patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg) every 24 hours and after dialysis.
Child administration
The dose for children (3 months~12 years) is calculated according to body surface area and administered in accordance with the adult dosage. Children (3 months~12 years), herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infections: Administer 250 mg per ㎡ of body surface area every 8 hours. Children (3 months~12 years), immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately in pediatric patients with renal impairment according to the degree of impairment.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex (encephalitis, genital herpes, etc.); treatment of chickenpox and shingles

  • Primary genital herpes
  • recurrent genital herpes
  • herpes simplex virus infections affecting skin and mucosal tissues
  • herpes zoster virus infections
  • acute pain
  • chickenpox
  • severe primary genital herpes
  • recurrent herpes zoster virus infections
  • herpes simplex encephalitis
  • herpes simplex virus infections
  • primary herpes zoster virus infections
  • recurrent herpes zoster virus infections.
View approved original text

This medication is available in various forms and is primarily used for the treatment and prevention of herpes simplex virus infections affecting skin and mucosal tissues, including primary and recurrent genital herpes. It is also effective in relieving acute pain from herpes zoster virus infections and is used for the treatment of chickenpox in children aged over 2 years. The injectable form is used in patients with normal immune function for the treatment of severe genital herpes, chickenpox, herpes zoster virus infections, and herpes simplex encephalitis. In immunocompromised patients, it is used for the treatment and prevention of herpes simplex virus infections, chickenpox, and herpes zoster virus encephalitis. This medication helps treat various infections and improve the patient's condition.

How it is given

Adult administration

For injection, administer by slow intravenous drip infusion over at least 1 hour at each dose. A treatment period of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg every 8 hours. Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this drug 5 mg/kg every 8 hours. Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer this drug 10 mg/kg every 8 hours. Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this drug 10 mg/kg every 8 hours. Prevention of herpes simplex virus infections in immunocompromised patients: Consider this treatment when oral administration is not possible. Determine the treatment duration according to the period of risk of infection. When acyclovir is administered intravenously to obese patients based on actual body weight, plasma concentrations may increase. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or elderly patients. Creatinine clearance 25~50 mL/min: Administer the recommended dose for the above indication every 12 hours. Creatinine clearance 10~25 mL/min: Administer the recommended dose for the above indication every 24 hours. Creatinine clearance 0 (anuria)~10 mL/min: In patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg) every 24 hours. In patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg) every 24 hours and after dialysis.

Child administration

The dose for children (3 months~12 years) is calculated according to body surface area and administered in accordance with the adult dosage. Children (3 months~12 years), herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infections: Administer 250 mg per ㎡ of body surface area every 8 hours. Children (3 months~12 years), immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately in pediatric patients with renal impairment according to the degree of impairment.

Precautions

This medication should absolutely not be administered to patients who have had hypersensitivity reactions to this medication or its components. Patients with impaired kidney function may be more susceptible to neuropsychiatric adverse reactions while using this medication, hence caution is necessary. Patients with compromised liver function should also be administered this medication with caution as liver function may deteriorate further. Children and infants should use this medication cautiously, especially newborns or low-birth-weight infants, as safety has not been established; it should be administered only when absolutely necessary. Elderly patients are likely to have reduced kidney function which may lead to increased blood concentration of this medication and heightened occurrence of side effects, necessitating careful adjustment of dosage and administration intervals. Although rare, serious allergic reactions such as anaphylactic shock may occur when using this medication, so if symptoms like hypotension, difficulty breathing, or chest tightness occur, administration should be stopped immediately, and appropriate treatment should be sought. Hypersensitivity reactions such as skin rashes, fever, vesicles, and urticaria may occur, so administration should be discontinued if these symptoms develop. Alopecia, severe skin rashes, and abnormalities in skin or mucous membranes have also been reported; if such symptoms appear, the physician should be consulted immediately. Neuropsychiatric symptoms can include altered consciousness, confusion, seizures, hallucinations, anxiety, drowsiness, tremors, etc., and these may occur more frequently in the elderly or those with renal impairment, necessitating precautions. Kidney function abnormalities may lead to renal failure, hematuria, proteinuria, etc., so regular kidney function tests should be conducted. Liver function abnormalities may manifest as hepatitis, jaundice, or elevated liver enzymes, hence liver function tests are also required. Gastrointestinal symptoms may include gastritis, nausea, vomiting, and abdominal pain, and if these symptoms are severe, administration should be discontinued. Sufficient hydration is important during administration of this medication, and especially when high doses are given, dehydration should be prevented to minimize the risk of nephrotoxicity. This medication may interact with other drugs, so when taken with medications such as probenecid, cimetidine, theophylline, or mycophenolate mofetil, consulting with a physician or pharmacist is essential. Pregnant women or women of childbearing potential should only use this medication if the therapeutic benefit outweighs the risks, as the components of this medication can be excreted in breast milk; breastfeeding should be discontinued during treatment. In the case of an overdose, severe symptoms such as agitation, coma, seizures, and somnolence may occur; careful monitoring of blood concentration is needed, and treatments like dialysis may be necessary if indicated. The most effective use of this medication starts as soon as symptoms appear, specifically within 5 days for herpes zoster and within 3 days for chickenpox. Injectable forms should not be administered as a rapid intravenous injection but must be administered as a slow intravenous drip; care must be taken to prevent the solution from extravasating to avoid vascular injury.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • dyspnea
  • chest tightness
  • phototoxic reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 141 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration impairment
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • convulsions
  • drowsiness
  • tremors
  • excitement
  • forgetfulness
  • insomnia
  • anxiety
  • soliloquy
  • paresthesia
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • renal failure
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary erythrocyte casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • lethargy
  • generalized fatigue
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glucose in urine
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • hypoproteinemia
  • elevated total cholesterol
  • elevated triglycerides
  • elevated serum potassium
  • decreased serum albumin
  • nonsensical speech
  • language disorder
  • paresthesia of the lower limbs
  • numbness of the tongue and extremities
  • hypersomnolence
  • generalized fatigue
  • bipolar disorder
  • emotional instability
  • concentration impairment
  • forgetfulness
  • ataxia
  • soliloquy
  • gait abnormalities
  • involuntary movements
  • dysuria
  • agranulocytosis
  • disseminated intravascular coagulation
  • gastric discomfort
  • hypotension
  • edema
  • feeling cold
  • laryngitis
  • sensation of tightness in the chest
  • ulcers
  • angina
  • vascular weakness
  • chromosomal abnormalities
  • mutations
  • decreased spermatogenesis
  • anxiety
  • coma
  • epileptic seizures
  • confusion
  • excitement

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container in a cool, dry place, maintaining a temperature between 15 to 25 degrees Celsius. Proper storage will help maintain the efficacy of the medication and prevent deterioration.

Appearance and packaging

Appearance

This medication is a white powder or granules contained in a colorless and transparent vial to be dissolved before use for injection.

Package unit

5 vials/box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.